Sfoglia per Autore
GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOINSTITUTIONAL EXPERIENCE
2008 M.Di Marco ;M. Macchini; R. Di Cicilia ; E. Nobili ; G. Biasco
Gemox in combination witherlotinib (E) in pancreatic cancer (PC).
2008 R. Di Cicilia;M. Macchini; M. Di Marco;E. Nobili;L.Calculli;R. Casadei; G.Biasco
Advanced pancreatic cancer (apc); a Monocenter experience in 53 patients. It is possible a second line treatment?
2009 Di Marco M; Macchini M; Di Cicilia R; Nobili E; Biasco G.
Advanced pancreatic cancer (APC) A monocenter experience in 53 patients: is it possible a second line treatment?
2009 Di Marco M; Macchini M; Di Cicilia R; Nobili E; Biasco G.
Role of adjuvant chemoradiotherapy (CRT) and chemotherapy alone in pancreatic cancer: experience in 25 patients.
2009 Macchini M; Di Cicilia R; Vecchiarelli S; de Rosa F; Nobili E; Di Marco M; Biasco G.
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: an interim report of a prospective controlled randomized study.
2009 D'Ambra M; casadei R; Pezzilli R; calculli L; Barbieri E; Di Marco M; Rega D; Ricci C; Macchini M; angelelli B; Serra C; Bruno A; lega S; santini D; Minni F.
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study
2010 M. Di Marco; M. Macchini; R. di Cicilia; S. Vecchiarelli; R. Casadei; E. Barbieri; L. Calculli; M. A. Pantaleo; G. Biasco
Long-Term Survival After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Case Report
2010 Buscemi S; Laterza M; Monari F; D’ambra M; Alagna V; Rega D; Ricci C; Taffurelli G; Pezzilli R; Di Marco M; Macchini M; Calculli L; Santini D; Casadei R; Minni F
GemOx and Ovarian Pancreatic Cancer Metastasis (PC)
2010 Pallotti MC; Vecchiarelli S; Macchini M; Di Marco M; D’Ambra M; Ferroni F; Poli F; Calculli L; Minni F; Casadei R; Santini D; Biasco G
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action
2010 Macchini M; Brandi G; Tavolari S; Guarnieri T; de Rosa F; Paterini P; Di Girolamo S; Agostini V; Di Marco M; Vecchiarelli S; Di Cicilia R; Nobili E; Biasco G.
Prognostic factors in resected pancreatic cancer:a single centre experience
2010 M.Di Marco;M.Macchini|;M.D'ambra;C.Ricci|;S.Vecchiarelli;M.C.Pallotti;;B.Melotti;F.Sperandi;R.Pezzilli;L.Calculli;D.Santini;E.Barbieri;C.Serra;R. Casadei;F.Minni;A.A.Martoni;G.Biasco
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment?
2010 Di Marco M; Di Cicilia R; Macchini M; Nobili E; Vecchiarelli S; Brandi G; Biasco G
Neoadjuvant Therapy for Resectable Pancreatic Adenocarcinoma: An Interim Report of a Prospective Controlled Randomized Study
2010 M. D’Ambra; R. Casadei; R. Pezzilli; L. Calculli; E. Barbieri; M.C. Di Marco; D. Rega; C. Ricci; M. Macchini; B. Angelelli; C. Serra; A. Guido; S. Lega
Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience.
2010 Nobili E; Di Cicilia R; Di Battista M; Morselli-Labate AM; Paragona M; Corbelli J; Macchini M; Prandoni P; Biasco G; Brandi G.
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases
2011 Di Marco M; Macchini M; Vecchiarelli S; Casadei R; Pezzilli R; Fanti S; Zanoni L; Calculli L; Barbieri E; Santini D; DI Cicilia R; Brandi G; Biasco G.
The follow-up issues: from the necessity to the opportunity
2011 Brandi G; Nannini M; Longobardi C; Maleddu A; Saponara M; Di Tullio P; Degli Esposti C; Katzinas J; Di Girolamo S; de Rosa F; Agostini V; Macchini M; Rubino D; Pini S; Pallotti M; Paragona M; Lolli C; Corbelli J; Garajovà I; Vecchiarelli S; Mandrioli A; Zucchini G; Pantaleo MA; Di Marco M; Cucchetti A; Biasco G.
Prognostic factors for recurrence in resected pancreatic adenocarcinoma: a single center experience
2011 Di Marco M; Macchini M; Ricci C; Taffurelli G; D'Ambra M; Vecchiarelli S; Pallotti MC; Pezzilli R; Martoni AA; Casadei R; Biasco G
Role of CA 19-9 Concentration as an Independent Prognostic Factor in Unresectable Pancreatic Ductal Adenocarcinoma (PDCA) Treated with GemOx
2011 Macchini M; Vecchiarelli S; Sina S; Ricci C; Casadei R; Pezzilli R; Calculli L; Santini D; Biasco G; Di Marco M
CIRCULATING METALLOPROTEINASE-3 AND TISSUE INHIBITOR OF METALLOPROTEINASE-2 IN PATIENTS WITH DUCTAL PANCREATIC NEOPLASMS
2011 Vecchiarelli S; Macchini M; Di Marco M; Pezzilli R; Fabbri D; Imbrogno A; Casadei R; Melzi d’Eril G; Sina S; Biasco G
Comparing RECIST and Choi's Criteria After Neoadjuvant Chemoradiotherapy in Patients with Resectable Pancreatic Cancer
2011 Monari F; D'Ambra M; Ricci C; Buscemi S; Calculli L; Pezzilli R; Santini D; Di Marco MC; Macchini M; Casadei R; Minni F
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOINSTITUTIONAL EXPERIENCE | M.Di Marco ;M. Macchini; R. Di Cicilia ; E. Nobili ; G. Biasco | 2008-01-01 | - | s.n | 4.02 Riassunto (Abstract) | - |
| Gemox in combination witherlotinib (E) in pancreatic cancer (PC). | R. Di Cicilia;M. Macchini; M. Di Marco;E. Nobili;L.Calculli;R. Casadei; G.Biasco | 2008-01-01 | JOP. JOURNAL OF THE PANCREAS | s.n | 4.02 Riassunto (Abstract) | - |
| Advanced pancreatic cancer (apc); a Monocenter experience in 53 patients. It is possible a second line treatment? | Di Marco M; Macchini M; Di Cicilia R; Nobili E; Biasco G. | 2009-01-01 | JOP. JOURNAL OF THE PANCREAS | - | 4.02 Riassunto (Abstract) | - |
| Advanced pancreatic cancer (APC) A monocenter experience in 53 patients: is it possible a second line treatment? | Di Marco M; Macchini M; Di Cicilia R; Nobili E; Biasco G. | 2009-01-01 | ANNALS OF ONCOLOGY | - | 4.02 Riassunto (Abstract) | - |
| Role of adjuvant chemoradiotherapy (CRT) and chemotherapy alone in pancreatic cancer: experience in 25 patients. | Macchini M; Di Cicilia R; Vecchiarelli S; de Rosa F; Nobili E; Di Marco M; Biasco G. | 2009-01-01 | JOP. JOURNAL OF THE PANCREAS | - | 4.02 Riassunto (Abstract) | - |
| Neoadjuvant therapy for resectable pancreatic adenocarcinoma: an interim report of a prospective controlled randomized study. | D'Ambra M; casadei R; Pezzilli R; calculli L; Barbieri E; Di Marco M; Rega D; Ricci C; Macchini M...; angelelli B; Serra C; Bruno A; lega S; santini D; Minni F. | 2009-01-01 | JOP. JOURNAL OF THE PANCREAS | - | 4.02 Riassunto (Abstract) | - |
| Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study | M. Di Marco; M. Macchini; R. di Cicilia; S. Vecchiarelli; R. Casadei; E. Barbieri; L. Calculli; M.... A. Pantaleo; G. Biasco | 2010-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 4.02 Riassunto (Abstract) | - |
| Long-Term Survival After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Case Report | Buscemi S; Laterza M; Monari F; D’ambra M; Alagna V; Rega D; Ricci C; Taffurelli G; Pezzilli R; D...i Marco M; Macchini M; Calculli L; Santini D; Casadei R; Minni F | 2010-01-01 | JOP. JOURNAL OF THE PANCREAS | - | 4.02 Riassunto (Abstract) | - |
| GemOx and Ovarian Pancreatic Cancer Metastasis (PC) | Pallotti MC; Vecchiarelli S; Macchini M; Di Marco M; D’Ambra M; Ferroni F; Poli F; Calculli L; Mi...nni F; Casadei R; Santini D; Biasco G | 2010-01-01 | JOP. JOURNAL OF THE PANCREAS | - | 4.02 Riassunto (Abstract) | - |
| The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action | Macchini M; Brandi G; Tavolari S; Guarnieri T; de Rosa F; Paterini P; Di Girolamo S; Agostini V; ...Di Marco M; Vecchiarelli S; Di Cicilia R; Nobili E; Biasco G. | 2010-01-01 | JOP. JOURNAL OF THE PANCREAS | - | 4.02 Riassunto (Abstract) | - |
| Prognostic factors in resected pancreatic cancer:a single centre experience | M.Di Marco;M.Macchini|;M.D'ambra;C.Ricci|;S.Vecchiarelli;M.C.Pallotti;;B.Melotti;F.Sperandi;R.Pez...zilli;L.Calculli;D.Santini;E.Barbieri;C.Serra;R. Casadei;F.Minni;A.A.Martoni;G.Biasco | 2010-01-01 | I SUPPLEMENTI DI TUMORI | - | 4.02 Riassunto (Abstract) | - |
| Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? |
Di Marco M; Di Cicilia R; Macchini M; Nobili E; Vecchiarelli S; Brandi G; Biasco G |
2010-01-01 | ONCOLOGY REPORTS | - | 1.01 Articolo in rivista | - |
| Neoadjuvant Therapy for Resectable Pancreatic Adenocarcinoma: An Interim Report of a Prospective Controlled Randomized Study | M. D’Ambra; R. Casadei; R. Pezzilli; L. Calculli; E. Barbieri; M.C. Di Marco; D. Rega; C. Ricci; ...M. Macchini; B. Angelelli; C. Serra; A. Guido; S. Lega | 2010-01-01 | PANCREATOLOGY | - | 4.02 Riassunto (Abstract) | - |
| Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience. | Nobili E; Di Cicilia R; Di Battista M; Morselli-Labate AM; Paragona M; Corbelli J; Macchini M; Pr...andoni P; Biasco G; Brandi G. | 2010-01-01 | PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS | - | 1.01 Articolo in rivista | - |
| Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases |
Di Marco M; Macchini M; Vecchiarelli S; Casadei R; Pezzilli R; Fanti S; Zanoni L; Calculli L; Ba...rbieri E; Santini D; DI Cicilia R; Brandi G; Biasco G. |
2011-01-01 | ONCOLOGY LETTERS | - | 1.01 Articolo in rivista | - |
| The follow-up issues: from the necessity to the opportunity | Brandi G; Nannini M; Longobardi C; Maleddu A; Saponara M; Di Tullio P; Degli Esposti C; Katzinas ...J; Di Girolamo S; de Rosa F; Agostini V; Macchini M; Rubino D; Pini S; Pallotti M; Paragona M; Lolli C; Corbelli J; Garajovà I; Vecchiarelli S; Mandrioli A; Zucchini G; Pantaleo MA; Di Marco M; Cucchetti A; Biasco G. | 2011-01-01 | I SUPPLEMENTI DI TUMORI | - | 4.03 Poster | - |
| Prognostic factors for recurrence in resected pancreatic adenocarcinoma: a single center experience | Di Marco M; Macchini M; Ricci C; Taffurelli G; D'Ambra M; Vecchiarelli S; Pallotti MC; Pezzilli R...; Martoni AA; Casadei R; Biasco G | 2011-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 4.02 Riassunto (Abstract) | - |
| Role of CA 19-9 Concentration as an Independent Prognostic Factor in Unresectable Pancreatic Ductal Adenocarcinoma (PDCA) Treated with GemOx | Macchini M; Vecchiarelli S; Sina S; Ricci C; Casadei R; Pezzilli R; Calculli L; Santini D; Biasco... G; Di Marco M | 2011-01-01 | JOP. JOURNAL OF THE PANCREAS | - | 4.02 Riassunto (Abstract) | - |
| CIRCULATING METALLOPROTEINASE-3 AND TISSUE INHIBITOR OF METALLOPROTEINASE-2 IN PATIENTS WITH DUCTAL PANCREATIC NEOPLASMS |
Vecchiarelli S; Macchini M; Di Marco M; Pezzilli R; Fabbri D; Imbrogno A; Casadei R; Melzi d’Eril... G; Sina S; Biasco G |
2011-01-01 | I SUPPLEMENTI DI TUMORI | - | 4.02 Riassunto (Abstract) | - |
| Comparing RECIST and Choi's Criteria After Neoadjuvant Chemoradiotherapy in Patients with Resectable Pancreatic Cancer | Monari F; D'Ambra M; Ricci C; Buscemi S; Calculli L; Pezzilli R; Santini D; Di Marco MC; Macchini... M; Casadei R; Minni F | 2011-01-01 | JOP. JOURNAL OF THE PANCREAS | - | 4.02 Riassunto (Abstract) | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile